BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37120492)

  • 1. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
    Ji Y; Liu B; Chen L; Li A; Shen K; Su R; Zhang W; Zhu Y; Wang Q; Xue W
    Cell Oncol (Dordr); 2023 Oct; 46(5):1445-1456. PubMed ID: 37120492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer.
    Chen L; Ji Y; Li A; Liu B; Shen K; Su R; Ma Z; Zhang W; Wang Q; Zhu Y; Xue W
    Front Oncol; 2023; 13():1085569. PubMed ID: 36994207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
    Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
    Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
    Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Front Immunol; 2021; 12():622001. PubMed ID: 33737929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
    Jing N; Du X; Liang Y; Tao Z; Bao S; Xiao H; Dong B; Gao WQ; Fang YX
    J Exp Clin Cancer Res; 2024 May; 43(1):144. PubMed ID: 38745318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.
    Elhasasna H; Khan R; Bhanumathy KK; Vizeacoumar FS; Walke P; Bautista M; Dahiya DK; Maranda V; Patel H; Balagopal A; Alli N; Krishnan A; Freywald A; Vizeacoumar FJ
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
    Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
    Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR; Gan Y; Tang Y; Dong X
    EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
    J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
    Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
    Kemble J; Kwon ED; Karnes RJ
    Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel exosome based therapeutic intervention against neuroendocrine prostate cancer.
    Saini S; Sreekumar A; Nathani S; Asante DM; Simmons MN
    Sci Rep; 2024 Feb; 14(1):2816. PubMed ID: 38307935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
    Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC; Shen M; Aslan M; Liu S; Kumar M; Garcia-Marques F; Nguyen HM; Nolley R; Pitteri SJ; Corey E; Brooks JD; Stoyanova T
    Sci Rep; 2021 Jun; 11(1):13305. PubMed ID: 34172788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.